CanOmix

growth-positive

Israeli start-ups are taking advantage of the countrys flexible and progressive regulations to become leaders in marijuana research. With reliable clinical tests being crucial for advancing cannabis as a medical drug, researchers are advised to start their trials in Israel. Israeli start-ups are racing to gain a first-mover advantage in an industry projected to be worth $14 billion to $30 billion by the end of the decade. The market is still in its early stages, and there is a lot of new money coming into the scene. Companies in Israel are focusing on various aspects of the marijuana market, including breeding plants, mapping terpenes, carrying out clinical trials, and developing systems for plant care. While there is still reform needed in Israel and abroad, investors, scientists, and entrepreneurs expect significant changes in the industry in the near future.